Treatment of metastatic colorectal cancer:
in combination with fluoropyrimidine-based chemotherapy.
Treatment of metastatic breast cancer:
first-line treatment in combination with paclitaxel;
first-line treatment in combination with capecitabine (when treatment with other chemotherapy regimens, including taxanes or anthracyclines, is considered inappropriate). Patients who have received taxane and anthracycline-based adjuvant regimens for the past 12 months should not be given Avastin in combination with capecitabine.
Treatment of non-resectable common, metastatic or recurrent non-small cell lung cancer, with the exception of predominantly non-squamous lung cancer:
the first line of treatment in combination with platinum-derived chemotherapy.
Treatment of common non-resectable, metastatic or recurrent non-squamous non-small cell lung cancer with EGFR-activating mutations (EGFR – epidermal growth factor receptor) in adult patients:
the first line of treatment in combination with erlotinib.
Treatment of common and / or metastatic renal cell carcinoma in adult patients:
first-line therapy in combination with interferon alfa-2a.
Treatment of common (stage i B, i C and IV according to the International Federation of Obstetrics and Gynecology (FIGO)) classification of epithelial ovarian cancer, fallopian tube and primary peritoneal cancer in adult patients:
first-line therapy in combination with carboplatin and paclitaxel.
Treatment of the first recurrence of epithelial ovarian cancer, fallopian tube and primary peritoneal cancer sensitive to treatment with platinum drugs:
in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel in adult patients who have not received prior bevacizumab therapy or other VEGF inhibitors or agents targeted at the VEGF receptor.
Treatment of recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer resistant to platinum drug treatment:
in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in adult patients who have received no more than two previous chemotherapy regimens and who have not received prior bevacizumab therapy or other VEGF inhibitors or VEG-directed drugs.
Treatment of persistent, recurrent or metastatic cervical cancer:
in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in adult patients unable to receive platinum drug therapy.
Treatment of recurrent glioblastoma (WHO grade IV):
as monotherapy after pre-treatment with temozolomide.